Effective Treatment of Advanced Lung Cancer with Furmonertinib
Author Information
Author(s): Sun Kai, Wang Peng
Primary Institution: Department Oncology, Yidu Central Hospital of Weifang, Weifang, China
Hypothesis
Can furmonertinib provide significant clinical benefits to NSCLC patients with complex resistance mechanisms?
Conclusion
Furmonertinib can provide significant clinical benefit to NSCLC patients with complex resistance mechanisms, including those involving the PIK3CA/mTOR pathway.
Supporting Evidence
- Furmonertinib achieved a progression-free survival of 27 months for the patient.
- The patient had previously received ineffective treatments before furmonertinib.
- Genome sequencing revealed persistent EGFR exon20ins and PIK3CA mutations.
Takeaway
A woman with advanced lung cancer tried many treatments, but furmonertinib helped her live longer and feel better.
Methodology
The patient received multiple lines of therapy, including chemotherapy and immunotherapy, before furmonertinib treatment.
Limitations
Additional examinations were needed for a comprehensive diagnosis, and the study is based on a single case.
Participant Demographics
63-year-old Chinese woman with lung adenocarcinoma and clear cell renal cell carcinoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website